364 related articles for article (PubMed ID: 24631357)
1. Epiregulin: roles in normal physiology and cancer.
Riese DJ; Cullum RL
Semin Cell Dev Biol; 2014 Apr; 28():49-56. PubMed ID: 24631357
[TBL] [Abstract][Full Text] [Related]
2. Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2.
Riese DJ; Komurasaki T; Plowman GD; Stern DF
J Biol Chem; 1998 May; 273(18):11288-94. PubMed ID: 9556621
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of epidermal growth factor receptor 4 in oral leukoplakia.
Kobayashi H; Kumagai K; Gotoh A; Eguchi T; Yamada H; Hamada Y; Suzuki S; Suzuki R
Int J Oral Sci; 2013 Mar; 5(1):14-20. PubMed ID: 23492901
[TBL] [Abstract][Full Text] [Related]
4. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
5. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
6. Epiregulin promotes hair growth via EGFR-medicated epidermal and ErbB4-mediated dermal stimulation.
Choi N; Kim WS; Oh SH; Sung JH
Cell Prolif; 2020 Sep; 53(9):e12881. PubMed ID: 32700456
[TBL] [Abstract][Full Text] [Related]
7. High epiregulin expression in human U87 glioma cells relies on IRE1α and promotes autocrine growth through EGF receptor.
Auf G; Jabouille A; Delugin M; Guérit S; Pineau R; North S; Platonova N; Maitre M; Favereaux A; Vajkoczy P; Seno M; Bikfalvi A; Minchenko D; Minchenko O; Moenner M
BMC Cancer; 2013 Dec; 13():597. PubMed ID: 24330607
[TBL] [Abstract][Full Text] [Related]
8. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4.
Komurasaki T; Toyoda H; Uchida D; Morimoto S
Oncogene; 1997 Dec; 15(23):2841-8. PubMed ID: 9419975
[TBL] [Abstract][Full Text] [Related]
9. Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes.
Shelly M; Pinkas-Kramarski R; Guarino BC; Waterman H; Wang LM; Lyass L; Alimandi M; Kuo A; Bacus SS; Pierce JH; Andrews GC; Yarden Y
J Biol Chem; 1998 Apr; 273(17):10496-505. PubMed ID: 9553109
[TBL] [Abstract][Full Text] [Related]
10. Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review.
Patnaik SK; Chandrasekar MJN; Nagarjuna P; Ramamurthi D; Swaroop AK
Mini Rev Med Chem; 2022 Oct; 22(22):2831-2846. PubMed ID: 35549881
[TBL] [Abstract][Full Text] [Related]
11. Magnitude of Ubiquitination Determines the Fate of Epidermal Growth Factor Receptor Upon Ligand Stimulation.
Akimov V; Fehling-Kaschek M; Barrio-Hernandez I; Puglia M; Bunkenborg J; Nielsen MM; Timmer J; Dengjel J; Blagoev B
J Mol Biol; 2021 Oct; 433(21):167240. PubMed ID: 34508725
[TBL] [Abstract][Full Text] [Related]
12. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis.
Révillion F; Lhotellier V; Hornez L; Bonneterre J; Peyrat JP
Ann Oncol; 2008 Jan; 19(1):73-80. PubMed ID: 17962208
[TBL] [Abstract][Full Text] [Related]
13. Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes.
Toyoda H; Komurasaki T; Uchida D; Takayama Y; Isobe T; Okuyama T; Hanada K
J Biol Chem; 1995 Mar; 270(13):7495-500. PubMed ID: 7706296
[TBL] [Abstract][Full Text] [Related]
14. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.
Zhang X; Diaz MR; Yee D
Breast Cancer Res Treat; 2013 Jun; 139(2):351-60. PubMed ID: 23686416
[TBL] [Abstract][Full Text] [Related]
15. Novel Pituitary Actions of Epidermal Growth Factor: Receptor Specificity and Signal Transduction for
Hu Q; Xu S; Ye C; Jia J; Zhou L; Hu G
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31635309
[TBL] [Abstract][Full Text] [Related]
16. The Role of EREG/EGFR Pathway in Tumor Progression.
Cheng WL; Feng PH; Lee KY; Chen KY; Sun WL; Van Hiep N; Luo CS; Wu SM
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884633
[TBL] [Abstract][Full Text] [Related]
17. EGFR signaling in breast cancer: bad to the bone.
Foley J; Nickerson NK; Nam S; Allen KT; Gilmore JL; Nephew KP; Riese DJ
Semin Cell Dev Biol; 2010 Dec; 21(9):951-60. PubMed ID: 20813200
[TBL] [Abstract][Full Text] [Related]
18. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Feroz K; Williams E; Riese DJ
Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
[TBL] [Abstract][Full Text] [Related]
19. Anti-EGFR monoclonal antibodies which act as EGF, TGF alpha, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours.
Modjtahedi H; Komurasaki T; Toyoda H; Dean C
Int J Cancer; 1998 Jan; 75(2):310-6. PubMed ID: 9462724
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
